Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Naïve People With Both HIV-1 and Hepatitis B: 3-Year Outcomes From ALLIANCE

Conference Reports for NATAP

HIV Drug Therapy Glasgow 2024
10-13 November


Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Treatment-Naïve People With Both HIV-1 and Hepatitis B: 3-Year Outcomes From ALLIANCE

	HIV Glasgow; November 10-13, 2024; Glasgow, UK Publication attached Download the PDF here